Good afternoon. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I'm pleased to host this session with the management team from Dexcom. To my right is Jake Leach, who has been the CEO now for—
11 months.
I was going to say a year. Yep. And after transitioning from COO and CTO roles. And then we also have Jereme Sylvain, the CFO, who recently was added another title, COO, as he expands his operational responsibilities. So we'll have about 25 minutes for Q&A, and I'll kick things off. Jake, I just wanted to start with a high-level question, and maybe ask you to speak for a minute about where Dexcom is on its journey to transform diabetes care, and maybe give us a brief summary and commentary about how you think the company's performing this year.
Yeah. Thanks, Matt, and thanks everyone for joining us. As we mentioned, I've been in the seat for 11 months, but long history with Dexcom. Been at Dexcom for 22 years. Started when we were a startup, basically engineering, and led a lot of our product development over the years. And when I look at the opportunity in front of us, I couldn't be more excited. If you think about just, you take a big step back and look at the number of people in the world that have diabetes, it's over 600 million and growing rapidly. You look at the number of people that have pre-diabetes on their way to diabetes, that's going to put us over 1 billion people that this technology could have a significant impact on.
So, I think when we think about where we are in the trajectory, we're still very early days. Feels like we're just getting started as we look at continued expansion with coverage. Our growth algorithm revolves around generating access for CGM insurance reimbursement around the globe, then coming to market with the right product at the right price point for the different healthcare systems. I think we've been quite effective at doing that, both in the U.S. and abroad.
If you think about what we can do for an individual and help them with their understanding their behavior and how to impact their glucose levels, CGM is a very cost-effective technology. I do believe that we can reach hundreds of millions of people with this technology. Today, less than 2% of the people with diabetes are using CGM. Just talking about an incredibly large end market, and we have a remarkably unique technology, highly differentiated, and we're going to continue to innovate on it.
I want to get to market expansion in a second, but maybe first, Jereme, since we have you here, we could talk a little bit about the numbers. You set out an LRP this past year. You're kind of well on your way there. Could you summarize the LRP and talk about how you're executing against it so far?
Yeah. Thanks, and happy to go into it and really kind of progress really top, middle, and bottom. I think it's helpful. So we had an LRP earlier this year. We went out till 2030. Really, the algorithm here is 10%+ growth per year, with gross margin expansion up into the high- 60s and operating margin expansion to 29%-30% over that window. So far this year, making great progress against that. To that point, we're at the higher end of the guidance we had issued at the beginning of the year, and on track to have a record year in new patients overall. So really excited about that progress over time.
Certainly that algorithm, that 10%+ algorithm, we believe is something that is going to be in effect obviously every year. Certainly some of it's contingent in the longer term based on coverage expansion. But Jake talked about the opportunity here, and with some of the trials we've done, CONNECT being one of those trials, the opportunity for expansion of coverage is massive, and the economic benefit we can provide to society is massive. I would say we're going to progress well against that. I'm looking forward to turning the page on what I think has been an excellent year thus far. We've made great progress, even relative to 2025 on operating margin.
Last year, we came in around 21%. This year, we're clocking in at 24%. So good progress there. I'd expect that progress to continue. And we're putting all the levers in the business today, like 15-day, some of the operations work we're doing, and certainly some of the work we're doing around technology and how we deliver services efficiently, that I think are going to set us up for years to come.
Great. Maybe turning back to the near-term coverage expansion, it's been highly anticipated, kind of waiting on bated breath here. Maybe you could talk about your confidence in actually getting the coverage, what's underpinning that, and what we should think about in terms of timing.
Yeah. Very exciting time with the CONNECT data being published in the New England Journal of Medicine. And as Matt mentioned, we're awaiting CMS approval for broad type two coverage in the United States for Medicare. And really, that decision is an evidence-based decision. So they're looking at, is there enough evidence to show the benefit in the Medicare population, the Medicare beneficiaries? The CONNECT study is irrefutable, the impact that CGM had on all categories of type two, both those using glucose-lowering medications of all types, GLP-1s, SGLT2s, even metformin, as well as those who weren't using any type of glucose-lowering medication.
Significant improvements in glucose control and A1C across that whole category in just six months. And so, that data is extremely strong now that it's published in the New England Journal. It's actually been accessed as one of the top 5% manuscripts being accessed at the New England Journal of Medicine. Very popular. We're using that to make sure we spread awareness. When it gets to CMS, we've had multiple conversations. When we submitted for this coverage in early 2025, the evidence was strong. We had a lot of real-world evidence that's continued to build. But now with CONNECT, I think it's kind of the cornerstone, the capstone on the evidence base. Now it's just a matter of time.
We've been assured, we've checked in multiple levels of CMS, as well as multiple folks in Congress and the Senate. Everyone has assured us that it is progressing, and it is an evidence-based decision. We look forward to hearing back before the end of the year. Just one other note, we do anticipate once we hear back, there's a comment period, and then there's administrative work. We're estimating if we hear back by the end of the year, we'll see that coverage really kick in in the market, for patients to experience reimbursement, middle of 2027.
Great. Maybe just remind us, how much is sort of baked into your LRP around that non-insulin type two coverage and growth from that segment?
Want to take that?
Want me to? In the LRP longer term, we come into this year sub 5% penetration in this market. I think in the out years of our LRP, we are really only assuming 10%-15%, depending on kind of the mix and where you land on the 10%+ . The opportunity to go beyond that obviously is massive. That is what the expectations are. Not because of any other reason other than, I think, one, it makes sense to be prudent.
Two, it is going to be on us as CGM manufacturers to build the product that is necessary for folks to fully benefit from it. I hope, for folks that have seen our Stelo product and the new Stelo app, you can probably envision what it looks like longer term in providing the so what do you do with it? I think that is the starting point. It is really only 10%-15% penetrated at the end of our LRP, which leaves a lot of room to go.
Maybe you could talk about some of the green shoots you are seeing in places where there is coverage today, because a lot of the PBMs have covered it a priori, before Medicare, which is not normal, but good. Also you have presented some real-world data on wear time. Can you talk about utilization and uptake, where there is coverage today?
Yeah. In that population that has commercial coverage in the United States for CGM, these are folks who have type two diabetes, not on insulin. Our real-world evidence, we have had this coverage for a little over a year now. We have been able to capture a registry of these folks and track their progress of use of the technology. We see about 80% utilization of CGM, which is quite solid for that population. One of the things we see is, in order to get the true benefit from CGM and the learnings, and the accountability, the behavior modification, it requires you to use the technology. If we look at the CONNECT study, we saw even higher utilization.
Granted, it was a clinical study, but the outcomes are driven by the use of the technology. We do see that type two patients, particularly in a reimbursed environment where it's low out-of-pocket cost, reduces the friction in accessing the technology, it drives really significant outcomes for these folks. We also see, if they do stop using it, they start to lose the benefit that they gained with the CGM in terms of glucose control quite quickly.
In all the clinical studies we've run, when we discontinue CGM use, which is hard because most people want to keep using it, but when they do discontinue, we do see a relapse, then likely they'll come back around and start CGM again. So, it's a technology that we believe can make an impact for someone's entire lifetime.
I just want to ask, you teased some potential benefits in the future for the pre-diabetes population, which is much larger. Could you talk about any evidence that you're working on or that you've generated so far, and any formal plans to do studies in that group?
Yeah, it's a great question. So, as we've wrapped up CONNECT, the next area of focus for clinical generation of evidence is in the pre-diabetes space. We believe, actually if you saw, we had an approval TEMPO, which is a specialized FDA program, that allows us to put new innovation digital technology into the market. One of the focuses of that program is to screen for diabetes, and risk of progression from pre-diabetes to type two diabetes. That's one of the things that CGM can show that an A1C doesn't. A1C is a single point in time, single blood reading. When you look at CGM, we can see that the risk levels of how quickly you will progress to type two diabetes are evident in that first two weeks of wearing a CGM.
The other opportunity is insulin resistance, which is the precursor to pre-diabetes. You can see in those traces of glucose continuous that we can start to see that insulin resistance long before it shows up in an A1C. So, the opportunity of the technology to help people understand where their risk levels are and where they are in their progression of metabolic disorder, then being the tool that can be used in real time through continuous wear to help change the course of that health trajectory. I do believe that over time, CGM will be a major component to changing the curve of diabetes around the globe, just because of its effectiveness at helping empower the individual to make the changes they need.
Most of it is just a lack of understanding. The CONNECT study, if we go back to diabetes, those folks on average were measuring their glucose three times a week. They're not managing their diabetes based on glucose readings. They're taking medication. You introduce the CGM, very significant opportunity for them to make changes that don't have to be that large. Even a subtle change can have a huge impact over time.
Great. Thank you. Maybe we could circle back, and could you talk about some of the recent chatter in the market about pricing, some potential slowing in the market? What are you seeing in terms of volume, pricing, and competition, and what do you think the outlook is for the market in the near term?
I'll start on what we're seeing, and then Jereme, you want to fill in on some of the pricing dynamics. If you look at our growth trajectory, we're very confident in our plans. We just updated our guide to the top end of what we guided in the range at the beginning of the year. We're on track for a record number of new patients this year, primarily coming from type two insulin users and type two non-insulin users where there's coverage.
In the United States, that's really driving the business. Then we look internationally, we're seeing good uptake of the technology, particularly in type two intensive insulin. Still a lot of work to do in the basal space. As we look, we're not seeing maybe what some others are seeing in terms of a slowdown. We're continuing to grow as expected, and like I said, record new patients this year is a good indication that our technology in the current environment is the sensor of choice.
Yeah, and maybe this helps provide context. You look at the total dollar value of growth year-over-year, at least in our business, and it's relatively similar in 2025- 2026 than it was from 2024- 2025. That's an indicator that from a total growth perspective and introducing new patients, even with some of the mix and price headwinds, we're still growing the dollar values very similar. We hear the noise as well. I think it's more of maybe a misinterpretation over time.
If you actually step back and look at the market, we've been growing in the double digits every quarter. Our biggest competitor has been in the high single digits, and the third competitor has been up in significant double digits as they've kind of gotten their sensor fixed, a little bit figured out in conjunction with their pump. The market's doing okay. When you look at it just objectively, it's doing well. I think slowdown is the wrong word. It's been pretty consistent business.
Well, you did, in the U.S., gain noticeable share in Q3. Maybe you could talk about some of the things that are driving the share gains and help people gain better understanding of what separates you competitively in the U.S.
Yeah. So we did take share across the different patient segments, both type two insulin users and non-insulin users, and it's really coming on the back of the launch of the G7 15-day product as we continue to roll that technology out. It's the most accurate, longest-lasting sensor available, and what we're seeing is physicians are choosing that product for patients, and patients are choosing it. That's a big part of this as we continue to advance the technology and the user experience. I think the outcomes that we're able to drive today are significantly driven by the fact that technology has improved so much.
If you go back to some of our earlier technologies, they were very effective in intensive insulin use, but as we've continued to move into less intensive insulin and even non-insulin users, the user experience around the product, the reliability of the technology, and the ease of use are all things that are why Dexcom is a sensor that people choose to use. We are going to continue driving that innovation and that experience so that we can serve more and more patients.
Maybe we could also spend a minute on international. I would just love you to articulate your international expansion strategy and maybe talk about some of the low-hanging fruit opportunities in terms of coverage expansion, some of the new countries that you could move into or drive penetration in, and the go-direct strategy as well.
Yeah. I'll start with the broad opportunity, and then we just announced some go-direct specifics in the European region that Jereme can definitely add some color on. So, taking a step back, the biggest opportunity for growth in the long run is outside the United States. If you look at the populations of people that have diabetes, as I mentioned, so much opportunity, and we're just in the early innings of access for type two. We have pretty good type one coverage in many markets outside the U.S. in access and penetration. But if you look at type two, most international markets don't cover CGM for basal insulin users. That's a good significant population of type two.
Even some, we're still working through MDI and type two. But the coverage continues to come. We had some great wins last year in type two MDI, and we anticipate that to continue. One of the maybe differences from our current strategy as opposed to what we historically have done is, our goal now is to be the one facilitating opening up that access and then being in the market with the right product portfolio to take advantage of the access. Maybe in the past, we were more focused on the U.S. market and kind of let others be the entry point into those markets.
We now want to be there when the coverage comes so that we can take advantage and make sure people get the Dexcom CGM technology that they can benefit from. As we look at access expansion, the CONNECT study is going to change the standard of care here in the United States so that all people with diabetes should be recommended CGM. As we move outside the United States, there is no reason why that study, and some additional ones that we will do, continue to drive the fact that CGM is substantially beneficial for both the users and the healthcare systems.
If you look at just the cost savings in the first year through eliminating emergency hospital room visits, extra utilization of the healthcare because people are having a challenge managing their diabetes, those savings are pretty clear in the first year. If you look at the long-term savings, so you take a long view on this, when someone is managing their glucose to appropriate levels, you do not have some of the complications like diabetic retinopathy or other chronic diseases that are fueled by diabetes.
Those savings are going to compound over the long run. We do feel that there are many payer systems and healthcare systems that are looking at it from a perspective of long-term savings, and that is where CGM is ripe to have a big impact. Jereme, you want to talk a little bit about some of the direct market?
Yeah. One of the big opportunities is also going direct in a lot of markets. What we found is, when you look at historically, we have either acquired our way into or taken direct in other ways a lot of the international markets. One of it is about building infrastructure, one of it is about having the right people, the connections, et c. We have done a better job of doing it more organically in more recent years, but we do have some large legacy businesses that were built on distributorships, and the largest one that remains, we will take direct.
The great news about when we go direct in these markets is a lot of times, the distributor can take you to a certain point, and that point typically stops as you move out of kind of the easier endocrinologist-focused type delivery models. It takes a little bit of investment and work to get into primary care physician. We have done it in the U.S., we have done it in a lot of places in Europe. In those markets where we find that is the case, it is time for us to go direct.
We are going to continue to look at these go directs because we think once we take it on, we can make the investment, and that investment turns into a pretty darn good return pretty quickly, especially as the manufacturer of the product as opposed to just the distributor of the product. So we will continue to do that. The large one we talked about, it will be in the middle of 2027. We will have more specifics on the date when we get there. That is going to be our strategy over the longer term, is to go direct where it makes sense. I think it is a good opportunity for us.
Got it. Maybe we will spend a minute on the support model because you announced at Q3 that you are standing up a support model for the CMS coverage and trying to help people with their access through DME and to sort out all the reimbursement challenges that people have. Could you talk a little bit about that strategy and how it could support that initiative and also kind of the PCP providers who may not have as much infrastructure?
Yeah, it is a great question. We are, come January next year, standing up a service called Dexcom Direct. The idea there is to help patients and physicians navigate coverage landscapes. Unfortunately, it can be quite challenging at times to determine exactly what the right solution for a patient is, whether they have a pharmacy benefit or potentially a medical benefit. Those go down different routes, and so really being there to help a patient understand what the best option for them is really what this is about. When we look at it is well worth making that investment upfront because the long-term value of someone using CGM and the benefits they are going to get in the long run are worth the investment upfront to make sure they get the right technology.
We are going to stand up that service. We are going to continue to enhance it over time. When we studied what gets in the way of CGM use, the friction for access, the reimbursement, how to get the product, how to get it paid for, where to get it, that is one of the biggest barriers to entry into CGM and use of CGM. As we stand up Dexcom Direct, the idea is to alleviate that friction and make it easy for patients to use the product. When someone is able to access the product at a low out-of-pocket cost, we see very strong utilization and very good retention. Our goal is to retain folks for life and make sure that they have the benefit of CGM for their entire lifetime.
Great. With the few minutes we have left, maybe we will touch on the pipeline and some margin stuff. On the pipeline, got some exciting things happening toward the end of 2027 into 2028 with the G8 platform, which will have dual analyte capabilities, and you have talked about potassium, potentially ketones. Maybe we could start on that. Could you talk about what G8 really brings to the table and improves over G7, and when we should expect some of those other analytes to come into play?
Yeah. So, incredibly excited about our next-gen hardware platform. This will be G8, eighth- generation of sensor technology. It is a whole redesign of the wearable, so the on-body component. It is 50% smaller than G7. One of the big design aspects was to make the device smaller but pack in even more functionality. As Matt mentioned, it is multi-analyte capable. It also has some new technology in it that we have been working on for a very long time that allows us to interrogate the glucose sensor and adapt its performance so that we can drive even greater sensor accuracy and reliability. I mentioned some of the challenges with CGM.
One of the barriers is access. The other reason why some people discontinue CGM is because even today, with the most accurate G7 sensor, sometimes it does not meet their expectations in terms of performance. We feel G8 is another kind of step change in accuracy, reliability. That matters for all patients, not just our AID users. Very important for them, but if you think about the acuity curve, you start going down towards type two diabetes, but you go to pre-diabetes where glucose levels are not changing nearly as much as someone with type one or type two diabetes or even insulin resistance.
Accuracy matters a lot. If you are off by 10%, that can be the difference between telling someone they have totally normal glucose and they have pre-diabetes. Accuracy is incredibly important for the entire spectrum of patients. So we feel G8 is a next-generation platform that is going to drive that type of performance. It will have multi-analyte capability. We are working on a number of multi-analytes. Potassium is one that we find uniquely interesting because it solves an unmet need.
Patients cannot monitor potassium at home. You cannot do it with a finger stick. You have to do it with a reasonably large blood draw in a lab. The reason why potassium is so important is because if potassium levels get out of range, particularly in chronic kidney disease, they can cause significant cardiac events, even cardiac arrest. Physicians are very wary of causing any kind of potassium disruption, and there are some medications out there that are quite effective for treating kidney disease, but because of the risks with potassium levels increasing, that they are not always used as effectively or as aggressively as they can be.
So, we feel that adding potassium to the glucose sensor for these patients that have diabetes and kidney disease is a really significant opportunity where we can drive an improved outcome that is worthy of reimbursement. And so, kind of taking from our playbook of diabetes, chronic disease, driving outcomes in other chronic diseases like kidney disease. We're also looking at liver disease. No timing yet on exactly when we're going to launch these.
They're well into development. We've been working on them for a number of years. Ketones is another one that we're working on as well, as well as lactate. These are very similar kind of sensors to what we make in the glucose oxidase realm in our current sensor, and so it's just basically adding that technology to the sensor probe. G8, the electronics were designed for multi-channels, so we can measure these different sensors all at the same time.
Great. Well, we're almost out of time. Maybe I'll just ask one about capital allocation. I thought one really notable change with the LRP was the commitment to cash flow and using that for buyback. So maybe you want to spend a minute on how we should think about use of cash and how that's evolved.
Yeah. When you look at the free cash flow we've been able to generate over the years, it's gotten significant. In the past, any cash flow generated would go into capital and building out facilities. At this point, we're well in excess of that. So the question was, how do we distribute this back to shareholders and/or how do we use it to invest in the business? We talked about areas investing in the business, like acquiring distributors and tuck-in technologies where it makes sense. We acquired a company called Nutrisense as a way to continue to expand our capabilities in this type two and beyond space.
But one of the other things we do is, as we're able to generate additional cash, one of the things we want to do is also return it back to shareholders. So that's one of the commitments we made is, as free cash flow continues to grow, we talked about returning at least half of it back to shareholders, and we're well on our way. We've done that in 2026. We announced our 2027 plan, which was another $1 billion in share buybacks. I think it's just our way to make sure that with the excess cash that we are generating, we're doing so both company-friendly but also shareholder-friendly.
Great. All right, great place to end. Thanks so much, guys, and thanks, everybody, for your interest in Dexcom.